Suppr超能文献

辛伐他汀与非诺贝特在人体内不存在具有临床意义的药代动力学相互作用。

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.

作者信息

Bergman Arthur J, Murphy Gail, Burke Joanne, Zhao Jamie J, Valesky Robert, Liu Lida, Lasseter Kenneth C, He Weili, Prueksaritanont Thomayant, Qiu Yue, Hartford Alan, Vega Jose M, Paolini John F

机构信息

Merck Research Laboratories, WP75-100, Sumneytown Pike, West Point, PA 19486, USA.

出版信息

J Clin Pharmacol. 2004 Sep;44(9):1054-62. doi: 10.1177/0091270004268044.

Abstract

Simvastatin and fenofibrate are both commonly used lipid-regulating agents with distinct mechanisms of action, and their coadministration may be an attractive treatment for some patients with dyslipidemia. A 2-period, randomized, open-label, crossover study was conducted in 12 subjects to determine if fenofibrate and simvastatin are subject to a clinically relevant pharmacokinetic interaction at steady state. In treatment A, subjects received an 80-mg simvastatin tablet in the morning for 7 days. In treatment B, subjects received a 160-mg micronized fenofibrate capsule in the morning for 7 days, followed by a 160-mg micronized fenofibrate capsule dosed together with an 80-mg simvastatin tablet on days 8 to 14. Because food increases the bioavailability of fenofibrate, each dose was administered with food to maximize the exposure of fenofibric acid. The steady-state pharmacokinetics (AUC(0-24h), C(max), and t(max)) of active and total HMG-CoA reductase inhibitors, simvastatin acid, and simvastatin were determined following simvastatin administration with and without fenofibrate. Also, fenofibric acid steady-state pharmacokinetics were evaluated with and without simvastatin. The geometric mean ratios (GMRs) for AUC(0-24h) (80 mg simvastatin [SV] + 160 mg fenofibrate)/(80 mg simvastatin alone) and 90% confidence intervals (CIs) were 0.88 (0.80, 0.95) and 0.92 (0.82, 1.03) for active and total HMG-CoA reductase inhibitors. The GMRs and 90% CIs for fenofibric acid (80 mg SV + 160 mg fenofibrate/160 mg fenofibrate alone) AUC(0-24h) and C(max) were 0.95 (0.88, 1.04) and 0.89 (0.77, 1.02), respectively. Because both the active inhibitor and fenofibric acid AUC GMR 90% confidence intervals fell within the prespecified bounds of (0.70, 1.43), no clinically significant pharmacokinetic drug interaction between fenofibrate and simvastatin was concluded in humans. The coadministration of simvastatin and fenofibrate in this study was well tolerated.

摘要

辛伐他汀和非诺贝特都是常用的调脂药物,作用机制不同,联合使用可能对一些血脂异常患者具有吸引力。一项为期2个阶段的随机、开放标签、交叉研究在12名受试者中进行,以确定非诺贝特和辛伐他汀在稳态时是否存在临床相关的药代动力学相互作用。在治疗A中,受试者在早晨服用80毫克辛伐他汀片,持续7天。在治疗B中,受试者在早晨服用160毫克微粉化非诺贝特胶囊,持续7天,然后在第8至14天,将160毫克微粉化非诺贝特胶囊与80毫克辛伐他汀片一起给药。由于食物会增加非诺贝特的生物利用度,每次给药都与食物一起服用,以最大限度地提高非诺贝特酸的暴露量。在辛伐他汀单独给药以及与非诺贝特联合给药后,测定活性和总HMG-CoA还原酶抑制剂、辛伐他汀酸和辛伐他汀的稳态药代动力学(AUC(0-24h)、C(max)和t(max))。此外,评估了非诺贝特酸在有和没有辛伐他汀情况下的稳态药代动力学。活性和总HMG-CoA还原酶抑制剂的AUC(0-24h)的几何平均比值(GMRs)(80毫克辛伐他汀[SV]+160毫克非诺贝特)/(单独80毫克辛伐他汀)和90%置信区间(CIs)分别为0.88(0.80,0.95)和0.92(0.82,1.03)。非诺贝特酸(80毫克SV+160毫克非诺贝特/单独160毫克非诺贝特)AUC(0-24h)和C(max)的GMRs和90% CIs分别为0.95(0.88,1.04)和0.89(0.77,1.02)。由于活性抑制剂和非诺贝特酸AUC的GMR 90%置信区间均落在预先设定的(0.70,1.43)范围内,因此得出结论,非诺贝特和辛伐他汀在人体中不存在临床显著的药代动力学药物相互作用。本研究中辛伐他汀和非诺贝特的联合使用耐受性良好。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验